Atrial selective effects of intravenously administered vernakalant in conscious beagle dogs

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 1, 2011, Pages 49-55

  Bechard, Jeff ^a   Pourrier, Marc ^a  

^a Cardiome Pharma Corp   (Canada)

Author keywords

antiarrhythmic; atrial selectivity; electrocardiogram; sotalol; vernakalant

Indexed keywords

SOTALOL; VERNAKALANT;

ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG SELECTIVITY; ELECTROCARDIOGRAM; HEART ATRIUM; HEART ATRIUM CONDUCTION; HEART RATE; HEART VENTRICLE CONDUCTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; P WAVE; PRIORITY JOURNAL; QRS COMPLEX;

ANIMALS; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FUNCTION; BLOOD PRESSURE; CONSCIOUSNESS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART ATRIA; HEART RATE; INFUSIONS, INTRAVENOUS; MALE; PYRROLIDINES;

EID: 79960406154     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821b8608     Document Type: Article

References (26)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006;48:854-906. (Pubitemid 44175743)
2. Page RL. Medical management of atrial fibrillation: future directions. Heart Rhythm. 2007;4(suppl 3):S91-S94.
3. Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res. 1984;55:278-285.
4. Varro A, Nakaya Y, Elharrar V, et al. Use-dependent effects of amiodarone on Vmax in cardiac purkinje and ventricular muscle fibers. Eur J Pharmacol. 1985;112:419-422. (Pubitemid 15042235)
5. Follmer CH, Aomine M, Yeh JZ, et al. Amiodarone-induced block of sodium current in isolated cardiac cells. J Pharmacol Exp Ther. 1987;243: 187-194. (Pubitemid 17162716)
6. Nishimura M, Follmer CH, Singer DH. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1989;251:650-659.
7. Polster P, Broekhuysen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol. 1976;25:131-134.
8. Gomoll AW, Bartek MJ. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. Eur J Pharmacol. 1986;132:123-135. (Pubitemid 17003451)
9. Vormberge T, Hoffmann M, Himmel H. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. J Pharmacol Toxicol Meth. 2006;54:130-140. (Pubitemid 44293424)
10. Internal Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (S7B). May 2005.
11. Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol. 1987;59:E32-E37.
12. Roy D, Rowe BH, Stiell IG, et al; and the CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial aibrillation. J Am Coll Cardiol. 2004; 44:2355-2361. (Pubitemid 39647610)
13. Roy D, Pratt CM, Torp-Pedersen C, et al; and Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008; 117:1518-1525. (Pubitemid 351440640)
14. Torp-Pedersen C, Karpenko Y, Raev D, et al. Oral vernakalant for the prevention of atrial fibrillation recurrence post-cardioversion. Eur Heart J. 2009;30(abstract suppl):450.
15. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227-1238.
16. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs. 2007;16:519-532. (Pubitemid 46554469)
17. Orth PM, Hesketh JC, Mak CK, et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res. 2006;70:486-496.
18. Dorian P, Pinter A, Mangat I, et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007;50:35-40. (Pubitemid 47220444)
19. Karjalainen J, Viitasalo M, Manttari M, et al. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol. 1994;23:1547-1553. (Pubitemid 24182117)
20. US food and drug administration. FDA guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. July 2005.
21. Schneider J, Hauser R, Andreas JO, et al. Differential effects of human ether-A-Go-Go-Related Gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol. 2005;512:53-60. (Pubitemid 40462363)
22. Sarubbi B, Ducceschi V, Briglia N, et al. Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease. Int J Cardiol. 1998;66: 157-164. (Pubitemid 29052341)
23. Beatch GN, Shinagawa K, Johnson BD, et al. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria. Pharmacologist. 2002;44(suppl 1):A15.
24. Bechard J, Gibson JK, Killingsworth CR, et al. Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs. J Cardiovasc Pharmacol. 2011;57:302-307.
25. Burashnikov A, Di Diego JM, Sicouri S, et al. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm. 2008;5:1735-1742.
26. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449-1457. (Pubitemid 47480635)